T cells in type 1 diabetes: Instructors, regulators and effectors: A comprehensive review

Journal of Autoimmunity

Volumn 66, Issue , 2016, Pages 7-16

  Gomez Tourino, Iria ^a   Arif, Sefina ^a   Eichmann, Martin ^a   Peakman, Mark ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Peak Therapeutics   (United Kingdom)

Author keywords

CD4 T cells; CD8 T cells; Inflammation; T cell receptor; Type 1 diabetes

Indexed keywords

AUTOANTIGEN; IMMUNOLOGIC FACTOR; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY;

AGE; ANTIGEN PRESENTATION; AUTOIMMUNITY; CD8+ T LYMPHOCYTE; DIABETES MELLITUS, TYPE 1; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; LYMPHOCYTE ACTIVATION; METABOLISM; PANCREAS ISLET BETA CELL; REGULATORY T LYMPHOCYTE;

AGE FACTORS; ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; AUTOANTIGENS; AUTOIMMUNITY; CD8-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INFLAMMATION; INSULIN-SECRETING CELLS; LYMPHOCYTE ACTIVATION; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, REGULATORY;

EID: 84953352655     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2015.08.012     Document Type: Review

References (125)

1. Katz J.D., Benoist C., Mathis D. T helper cell subsets in insulin-dependent diabetes. Science 1995, 268:1185-1188.
2. Arif S., Tree T.I., Astill T.P., Tremble J.M., Bishop A.J., Dayan C.M., et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J. Clin. Invest. 2004, 113:451-463.
3. Gomez-Tourino I., Simon-Vazquez R., Alonso-Lorenzo J., Arif S., Calvino-Sampedro C., Gonzalez-Fernandez A., et al. Characterization of the autoimmune response against the nerve tissue S100beta in patients with type 1 diabetes. Clin. Exp. Immunol. 2015, 180:207-217.
4. Arif S., Moore F., Marks K., Bouckenooghe T., Dayan C.M., Planas R., et al. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated beta-cell death. Diabetes 2011, 60:2112-2119.
5. Bellemore S.M., Nikoopour E., Schwartz J.A., Krougly O., Lee-Chan E., Singh B. Preventative role of IL-17 producing regulatory Th17 (Treg17) cells in type 1 diabetes in NOD mice. Clin. Exp. Immunol. 2015.
6. Tree T.I., Lawson J., Edwards H., Skowera A., Arif S., Roep B.O., et al. Naturally arising human CD4 T-cells that recognize islet autoantigens and secrete interleukin-10 regulate proinflammatory T-cell responses via linked suppression. Diabetes 2010, 59:1451-1460.
7. Petrich de Marquesini L.G., Fu J., Connor K.J., Bishop A.J., McLintock N.E., Pope C., et al. IFN-gamma and IL-10 islet-antigen-specific T cell responses in autoantibody-negative first-degree relatives of patients with type 1 diabetes. Diabetologia 2010, 53:1451-1460.
8. Arif S., Leete P., Nguyen V., Marks K., Nor N.M., Estorninho M., et al. Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes. Diabetes 2014, 63:3835-3845.
9. Nakayama M., Abiru N., Moriyama H., Babaya N., Liu E., Miao D., et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005, 435:220-223.
10. Stadinski B.D., Zhang L., Crawford F., Marrack P., Eisenbarth G.S., Kappler J.W. Diabetogenic T cells recognize insulin bound to IAg7 in an unexpected, weakly binding register. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:10978-10983.
11. Crawford F., Stadinski B., Jin N., Michels A., Nakayama M., Pratt P., et al. Specificity and detection of insulin-reactive CD4+ T cells in type 1 diabetes in the nonobese diabetic (NOD) mouse. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:16729-16734.
12. Nakayama M., McDaniel K., Fitzgerald-Miller L., Kiekhaefer C., Snell-Bergeon J.K., Davidson H.W., et al. Regulatory vs. inflammatory cytokine T-cell responses to mutated insulin peptides in healthy and type 1 diabetic subjects. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:4429-4434.
13. van Lummel M., Duinkerken G., van Veelen P.A., de Ru A., Cordfunke R., Zaldumbide A., et al. Posttranslational modification of HLA-DQ binding islet autoantigens in type 1 diabetes. Diabetes 2014, 63:237-247.
14. Danke N.A., Koelle D.M., Yee C., Beheray S., Kwok W.W. Autoreactive T cells in healthy individuals. J. Immunol. 2004, 172:5967-5972.
15. Gagliani N., Magnani C.F., Huber S., Gianolini M.E., Pala M., Licona-Limon P., et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat. Med. 2013, 19:739-746.
16. Brusko T.M., Wasserfall C.H., Clare-Salzler M.J., Schatz D.A., Atkinson M.A. Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes 2005, 54:1407-1414.
17. Lindley S., Dayan C.M., Bishop A., Roep B.O., Peakman M., Tree T.I. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005, 54:92-99.
18. Glisic-Milosavljevic S., Waukau J., Jailwala P., Jana S., Khoo H.J., Albertz H., et al. At-risk and recent-onset type 1 diabetic subjects have increased apoptosis in the CD4+CD25+ T-cell fraction. PLoS One 2007, 2:e146.
19. Schneider A., Rieck M., Sanda S., Pihoker C., Greenbaum C., Buckner J.H. The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J. Immunol. 2008, 181:7350-7355.
20. Lawson J.M., Tremble J., Dayan C., Beyan H., Leslie R.D., Peakman M., et al. Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin. Exp. Immunol. 2008, 154:353-359.
21. Ferraro A., Socci C., Stabilini A., Valle A., Monti P., Piemonti L., et al. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 2011, 60:2903-2913.
22. Vella A., Cooper J.D., Lowe C.E., Walker N., Nutland S., Widmer B., et al. Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am. J. Hum. Genet. 2005, 76:773-779.
23. Thompson W.S., Pekalski M.L., Simons H.Z., Smyth D.J., Castro-Dopico X., Guo H., et al. Multi-parametric flow cytometric and genetic investigation of the peripheral B cell compartment in human type 1 diabetes. Clin. Exp. Immunol. 2014, 177:571-585.
24. Thrower S.L., James L., Hall W., Green K.M., Arif S., Allen J.S., et al. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study. Clin. Exp. Immunol. 2009, 155:156-165.
25. Peakman M., von Herrath M. Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential. Diabetes 2010, 59:2087-2093.
26. von Herrath M., Peakman M., Roep B. Progress in immune-based therapies for type 1 diabetes. Clin. Exp. Immunol. 2013, 172:186-202.
27. Gibson V.B., Nikolic T., Pearce V.Q., Demengeot O., Roep B.O., Peakman M. Proinsulin multi-peptide immunotherapy induces antigen-specific regulatory T cells and limits autoimmunity in a humanised model. Clin. Exp. Immunol. 2015.
28. Planas R., Carrillo J., Sanchez A., de Villa M.C., Nunez F., Verdaguer J., et al. Gene expression profiles for the human pancreas and purified islets in type 1 diabetes: new findings at clinical onset and in long-standing diabetes. Clin. Exp. Immunol. 2010, 159:23-44.
29. Walker L.S., von Herrath M. CD4 T cell differentiation in type 1 diabetes. Clin. Exp. Immunol. 2015.
30. Becattini S., Latorre D., Mele F., Foglierini M., De Gregorio C., Cassotta A., et al. T cell immunity. Functional heterogeneity of human memory CD4(+) T cell clones primed by pathogens or vaccines. Science 2015, 347:400-406.
31. Mason G.M., Lowe K., Melchiotti R., Ellis R., de Rinaldis E., Peakman M., et al. Phenotypic complexity of the human regulatory T cell compartment revealed by mass cytometry. J. Immunol. 2015 Sep 1, 195(5):2030-2037.
32. Fan H.C., Fu G.K., Fodor S.P. Expression profiling. Combinatorial labeling of single cells for gene expression cytometry. Science 2015, 347:1258367.
33. Chen K.H., Boettiger A.N., Moffitt J.R., Wang S., Zhuang X. RNA imaging. Spatially resolved, highly multiplexed RNA profiling in single cells. Science 2015, 348:aaa6090.
34. Estorninho M., Gibson V.B., Kronenberg-Versteeg D., Liu Y.F., Ni C., Cerosaletti K., et al. A novel approach to tracking antigen-experienced CD4 T cells into functional compartments via tandem deep and shallow TCR clonotyping. J. Immunol. 2013, 191:5430-5440.
35. Yu W., Jiang N., Ebert P.J., Kidd B.A., Muller S., Lund P.J., et al. Clonal deletion prunes but does not eliminate self-specific alphabeta CD8(+) T lymphocytes. Immunity 2015, 42:929-941.
36. Eugster A., Lindner A., Catani M., Heninger A.-K., Dahl A., Klemroth S., et al. High diversity in the TCR repertoire of GAD65 autoantigen-specific human CD4(+) T cells. J. Immunol. 2015, 194:2531-2538.
37. Eugster A., Lindner A., Heninger A.K., Wilhelm C., Dietz S., Catani M., et al. Measuring T cell receptor and T cell gene expression diversity in antigen-responsive human CD4+ T cells. J. Immunol. Methods 2013, 400-401:13-22.
38. Turchaninova M.A., Britanova O.V., Bolotin D.A., Shugay M., Putintseva E.V., Staroverov D.B., et al. Pairing of T-cell receptor chains via emulsion PCR. Eur. J. Immunol. 2013, 43:2507-2515.
39. DeKosky B.J., Ippolito G.C., Deschner R.P., Lavinder J.J., Wine Y., Rawlings B.M., et al. High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire. Nat. Biotechnol. 2013, 31:166-169.
40. Birnbaum M.E., Mendoza J.L., Sethi D.K., Dong S., Glanville J., Dobbins J., et al. Deconstructing the peptide-MHC specificity of T cell recognition. Cell 2014, 157:1073-1087.
41. Nejentsev S., Howson J.M., Walker N.M., Szeszko J., Field S.F., Stevens H.E., et al. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 2007, 450:887-892.
42. Coppieters K.T., Dotta F., Amirian N., Campbell P.D., Kay T.W., Atkinson M.A., et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J. Exp. Med. 2012, 209:51-60.
43. Roep B.O., Kleijwegt F.S., van Halteren A.G., Bonato V., Boggi U., Vendrame F., et al. Islet inflammation and CXCL10 in recent-onset type 1 diabetes. Clin. Exp. Immunol. 2010, 159:338-343.
44. Skowera A., Ellis R.J., Varela-Calvino R., Arif S., Huang G.C., Van-Krinks C., et al. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J. Clin. Invest. 2008, 118:3390-3402.
45. Kronenberg D., Knight R.R., Estorninho M., Ellis R.J., Kester M.G., de Ru A., et al. Circulating preproinsulin signal peptide-specific CD8 T cells restricted by the susceptibility molecule HLA-A24 are expanded at onset of type 1 diabetes and kill beta-cells. Diabetes 2012, 61:1752-1759.
46. Knight R.R., Dolton G., Kronenberg-Versteeg D., Eichmann M., Zhao M., Huang G.C., et al. A distinct immunogenic region of glutamic acid decarboxylase 65 is naturally processed and presented by human islet cells to cytotoxic CD8 T cells. Clin. Exp. Immunol. 2015, 179:100-107.
47. Mallone R., Brezar V., Boitard C. T cell recognition of autoantigens in human type 1 diabetes: clinical perspectives. Clin. Dev. Immunol. 2011, 2011:513210.
48. Babad J., Mukherjee G., Follenzi A., Ali R., Roep B.O., Shultz L.D., et al. Generation of beta cell-specific human cytotoxic T cells by lentiviral transduction and their survival in immunodeficient human leucocyte antigen-transgenic mice. Clin. Exp. Immunol. 2015, 179:398-413.
49. Skarstrand H., Krupinska E., Haataja T.J., Vaziri-Sani F., Lagerstedt J.O., Lernmark A. Zinc transporter 8 (ZnT8) autoantibody epitope specificity and affinity examined with recombinant ZnT8 variant proteins in specific ZnT8R and ZnT8W autoantibody-positive type 1 diabetes patients. Clin. Exp. Immunol. 2015, 179:220-229.
50. Battaglia M., Atkinson M.A. The streetlight effect in type 1 diabetes. Diabetes 2015, 64:1081-1090.
51. Stadinski B.D., Delong T., Reisdorph N., Reisdorph R., Powell R.L., Armstrong M., et al. Chromogranin A is an autoantigen in type 1 diabetes. Nat. Immunol. 2010, 11:225-231.
52. Gottlieb P.A.D.T., Baker R.L., Fitzgerald-Miller L., Wagner R., Cook G.R.M., Michels A., Haskins K. Chromogranin A is a T cell antigen in human type 1 diabetes. J. Autoimmun. 2014, 50:38-41.
53. Hotamisligil G.S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010, 140:900-917.
54. Mannering S.I., Harrison L.C., Williamson N.A., Morris J.S., Thearle D.J., Jensen K.P., et al. The insulin A-chain epitope recognized by human T cells is posttranslationally modified. J. Exp. Med. 2005, 202:1191-1197.
55. McGinty J.W., Chow I.T., Greenbaum C., Odegard J., Kwok W.W., James E.A. Recognition of posttranslationally modified GAD65 epitopes in subjects with type 1 diabetes. Diabetes 2014, 63:3033-3040.
56. Meadows L., Wang W., den Haan J.M., Blokland E., Reinhardus C., Drijfhout J.W., et al. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 1997, 6:273-281.
57. Petersen J., Wurzbacher S.J., Williamson N.A., Ramarathinam S.H., Reid H.H., Nair A.K., et al. Phosphorylated self-peptides alter human leukocyte antigen class I-restricted antigen presentation and generate tumor-specific epitopes. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2776-2781.
58. Eichmann M., de Ru A., van Veelen P.A., Peakman M., Kronenberg-Versteeg D. Identification and characterisation of peptide binding motifs of six autoimmune disease-associated human leukocyte antigen-class I molecules including HLA-B*39:06. Tissue antigens 2014, 84:378-388.
59. Tynan F.E., Burrows S.R., Buckle A.M., Clements C.S., Borg N.A., Miles J.J., et al. T cell receptor recognition of a 'super-bulged' major histocompatibility complex class I-bound peptide. Nat. Immunol. 2005, 6:1114-1122.
60. Bulek A.M., Cole D.K., Skowera A., Dolton G., Gras S., Madura F., et al. Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes. Nat. Immunol. 2012, 13:283-289.
61. Paul S., Weiskopf D., Angelo M.A., Sidney J., Peters B., Sette A. HLA class I alleles are associated with peptide-binding repertoires of different size, affinity, and immunogenicity. J. Immunol. 2013, 191:5831-5839.
62. Unger W.W., Velthuis J., Abreu J.R., Laban S., Quinten E., Kester M.G., et al. Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers. J. Autoimmun. 2011, 37:151-159.
63. Dolton G., Lissina A., Skowera A., Ladell K., Tungatt K., Jones E., et al. Comparison of peptide-major histocompatibility complex tetramers and dextramers for the identification of antigen-specific T cells. Clin. Exp. Immunol. 2014, 177:47-63.
64. Blum J.S., Wearsch P.A., Cresswell P. Pathways of antigen processing. Annu. Rev. Immunol. 2013, 31:443-473.
65. Yewdell J.W. DRiPs solidify: progress in understanding endogenous MHC class I antigen processing. Trends Immunol. 2011, 32:548-558.
66. Neefjes J., Jongsma M.L., Paul P., Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat. Rev. Immunol. 2011, 11:823-836.
67. Hoelen H., Zaldumbide A., van Leeuwen W.F., Torfs E.C., Engelse M.A., Hassan C., et al. Proteasomal Degradation of Proinsulin Requires Derlin-2, HRD1 and p97. PLoS One 2015, 10:e0128206.
68. Luce S., Lemonnier F., Briand J.P., Coste J., Lahlou N., Muller S., et al. Single insulin-specific CD8+ T cells show characteristic gene expression profiles in human type 1 diabetes. Diabetes 2011, 60:3289-3299.
69. Roep B.O., Tree T.I. Immune modulation in humans: implications for type 1 diabetes mellitus. Nat. Rev. Endocrinol. 2014, 10:229-242.
70. Cole D.K., Pumphrey N.J., Boulter J.M., Sami M., Bell J.I., Gostick E., et al. Human TCR-binding affinity is governed by MHC class restriction. J. Immunol. 2007, 178:5727-5734.
71. Varela-Rohena A., Molloy P.E., Dunn S.M., Li Y., Suhoski M.M., Carroll R.G., et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat. Med. 2008, 14:1390-1395.
72. Sewell A.K. Why must T cells be cross-reactive?. Nat. Rev. Immunol. 2012, 12:669-677.
73. Rodriguez-Calvo T., Ekwall O., Amirian N., Zapardiel-Gonzalo J., von Herrath M.G. Increased immune cell infiltration of the exocrine pancreas: a possible contribution to the pathogenesis of type 1 diabetes. Diabetes 2014, 63:3880-3890.
74. Velthuis J.H., Unger W.W., Abreu J.R., Duinkerken G., Franken K., Peakman M., et al. Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes 2010, 59:1721-1730.
75. Skowera A., Ladell K., McLaren J.E., Dolton G., Matthews K.K., Gostick E., et al. beta-cell-specific CD8 T cell phenotype in type 1 diabetes reflects chronic autoantigen exposure. Diabetes 2015, 64:916-925.
76. Scotto M., Afonso G., Larger E., Raverdy C., Lemonnier F.A., Carel J.C., et al. Zinc transporter (ZnT)8(186-194) is an immunodominant CD8+ T cell epitope in HLA-A2+ type 1 diabetic patients. Diabetologia 2012, 55:2026-2031.
77. McKinney E.F., Lee J.C., Jayne D.R., Lyons P.A., Smith K.G. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 2015, 523:612-616.
78. Atkinson M.A.E.G., Michels A.W. Type 1 diabetes. Lancet 2014, 383:69-82.
79. Mannering S.I., Pathiraja V., Kay T.W. The case for an autoimmune aetiology of type 1 diabetes. Clin. Exp. Immunol. 2015, (in press).
80. von Herrath M.G., Korsgren O., Atkinson M.A. Factors impeding the discovery of an intervention-based treatment for type 1 diabetes. Clin. Exp. Immunol. 2015.
81. Liu E.E.G. Type 1A diabetes mellitus-associated autoimmunity. Endocrinol. Metab. Clin. North Am. 2002, 31:391-410.
82. Arif S.L.P., Nguyen V., Marks K., Nor N.M., Estorninho M., Kronenberg-Versteeg D.B.P., Todd J.A., Guy C., Dunger D.B., Powrie J.W.A., Foulis A.K., Richardson S.J., de Rinaldis E., Morgan N.G.L.A., Peakman M. Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes. Diabetes 2014, 63:3835-3845.
83. Ziegler A.G.R.M., Simell O., Simell T., Lempainen J., Steck A., Winkler C., Ilonen J.V.R., Knip M., Bonifacio E., Eisenbarth G.S. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013, 309:2473-2479.
84. Knip M.K.S., Kulmala P., Veijola R., Reunanen A., Raitakari O.T., Viikari J., HK A. Prediction of type 1 diabetes in the general population. Diabetes Care 2010, 33:1206-1212.
85. Bollyky J.B., Xu P., Butte A.J., Wilson D.M., Beam C.A., Greenbaum C.J. Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspective. Diabetes Metab. Res. Rev. 2015, Type 1 Diabetes, Group. TS.
86. Greenbaum C.J., Beam C.A., Boulware D., Gitelman S.E., Gottlieb P.A., Herold K.C., et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 2012, 61:2066-2073.
87. Hummel M.B.E., Schmid S., Walter M., Knopff A., Ziegler A.G. Brief communication: early appearance of islet autoantibodies predicts childhood type 1 diabetes in offspring of diabetic parents. Ann. Intern Med. 2004, 140:882-886.
88. Krischer J.P., Lynch K.F., Schatz D.A., Ilonen J., Lernmark A., Hagopian W.A., et al. The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia 2015, 58:980-987.
89. Achenbach P.H.M., Thümer L., Boerschmann H., Höfelmann D., Ziegler A.G. Characteristics of rapid vs slow progression to type 1 diabetes in multiple islet autoantibody-positive children. Diebetologia 2013, 56:1615-1622.
90. Willcox A.R.S., Bone A.J., Foulis A.K., Morgan N.G. Analysis of islet inflammation in human type 1 diabetes. Clin. Exp. Immunol. 2009, 155:125-127.
91. Morgan N.G.L.P., Foulis A.K., Richardson S.J. Islet inflammation in human type 1 diabetes mellitus. IUBMB Life 2014, 66:723-734.
92. Davis A.K.D.S.H.M., Miller K.M., DiMeglio L.A., Bethin K.E.G.R., Greenberg E.M., Liljenquist D.R., Ahmann A.J., Marcovina S.M.P.A., Beck R.W., Greenbaum C.J. T1D exchange clinic network. Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care 2015, 38:476-481.
93. Hummel K.M.K., Realsen J., Messer L.H., Klingensmith G.J., Chase H.P. The increasing onset of type 1 diabetes in children. J. Pediatr. 2012, 161:652-657.
94. Bhargava P., Calabresi P.A. Novel therapies for memory cells in autoimmune diseases. Clin. Exp. Immunol. 2015, 180:353-360.
95. Dunne J.L., Triplett E.W., Gevers D., Xavier R., Insel R., Danska J., et al. The intestinal microbiome in type 1 diabetes. Clin. Exp. Immunol. 2014, 177:30-37.
96. Peterson C.T., Sharma V., Elmen L., Peterson S.N. Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota. Clin. Exp. Immunol. 2015, 179:363-377.
97. Gitelman S.E., Gottlieb P.A., Rigby M.R., Felner E.I., Willi S.M., Fisher L.K., et al. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2013, 1:306-316.
98. Daifotis A.G., Koenig S., Chatenoud L., Herold K.C. Anti-CD3 clinical trials in type 1 diabetes mellitus. Clin. Immunol. 2013, 149:268-278.
99. Herold K.C., Gitelman S.E., Ehlers M.R., Gottlieb P.A., Greenbaum C.J., Hagopian W., et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013, 62:3766-3774.
100. Hagopian W., Ferry R.J., Sherry N., Carlin D., Bonvini E., Johnson S., et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protege trial. Diabetes 2013, 62:3901-3908.
101. Herold K.C., Gitelman S.E., Willi S.M., Gottlieb P.A., Waldron-Lynch F., Devine L., et al. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 2013, 56:391-400.
102. Sherry N., Hagopian W., Ludvigsson J., Jain S.M., Wahlen J., Ferry R.J., et al. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011, 378:487-497.
103. Herold K.C., Gitelman S., Greenbaum C., Puck J., Hagopian W., Gottlieb P., et al. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin. Immunol. 2009, 132:166-173.
104. Herold K.C., Gitelman S.E., Masharani U., Hagopian W., Bisikirska B., Donaldson D., et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005, 54:1763-1769.
105. Keymeulen B., Candon S., Fafi-Kremer S., Ziegler A., Leruez-Ville M., Mathieu C., et al. Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood 2010, 115:1145-1155.
106. Aronson R., Gottlieb P.A., Christiansen J.S., Donner T.W., Bosi E., Bode B.W., et al. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care 2014, 37:2746-2754.
107. Ambery P., Donner T.W., Biswas N., Donaldson J., Parkin J., Dayan C.M. Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study. Diabet. Med. 2014, 31:399-402.
108. Wooldridge L., Ekeruche-Makinde J., van den Berg H.A., Skowera A., Miles J.J., Tan M.P., et al. A single autoimmune T cell receptor recognizes more than a million different peptides. J. Biol. Chem. 2012, 287:1168-1177.
109. Pescovitz M.D., Greenbaum C.J., Krause-Steinrauf H., Becker D.J., Gitelman S.E., Goland R., et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 2009, 361:2143-2152.
110. Orban T., Bundy B., Becker D.J., DiMeglio L.A., Gitelman S.E., Goland R., et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011, 378:412-419.
111. Orban T., Bundy B., Becker D.J., Dimeglio L.A., Gitelman S.E., Goland R., et al. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care 2014, 37:1069-1075.
112. Orban T., Beam C.A., Xu P., Moore K., Jiang Q., Deng J., et al. Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline. Diabetes 2014, 63:3449-3457.
113. Marek-Trzonkowska N., Mysliwiec M., Dobyszuk A., Grabowska M., Derkowska I., Juscinska J., et al. Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up. Clin. Immunol. 2014, 153:23-30.
114. Marek-Trzonkowska N., Mysliwiec M., Dobyszuk A., Grabowska M., Techmanska I., Juscinska J., et al. Administration of CD4+CD25highCD127- regulatory T cells preserves beta-cell function in type 1 diabetes in children. Diabetes Care 2012, 35:1817-1820.
115. Tang Q., Henriksen K.J., Bi M., Finger E.B., Szot G., Ye J., et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 2004, 199:1455-1465.
116. Bluestone J.A., Bour-Jordan H., Cheng M., Anderson M. T cells in the control of organ-specific autoimmunity. J. Clin. Invest. 2015, 125:2250-2260.
117. Mekala D.J., Geiger T.L. Immunotherapy of autoimmune encephalomyelitis with redirected CD4+CD25+ T lymphocytes. Blood 2005, 105:2090-2092.
118. Brusko T.M., Koya R.C., Zhu S., Lee M.R., Putnam A.L., McClymont S.A., et al. Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PLoS One 2010, 5:e11726.
119. Elinav E., Adam N., Waks T., Eshhar Z. Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. Gastroenterology 2009, 136:1721-1731.
120. Hombach A.A., Kofler D., Rappl G., Abken H. Redirecting human CD4+CD25+ regulatory T cells from the peripheral blood with pre-defined target specificity. Gene Ther. 2009, 16:1088-1096.
121. Peakman M. Can we vaccinate against Type 1 diabetes?. F1000 Biol. Rep. 2012, 4:19.
122. Larche M., Wraith D.C. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat. Med. 2005, 11:S69-S76.
123. Sabatos-Peyton C.A., Verhagen J., Wraith D.C. Antigen-specific immunotherapy of autoimmune and allergic diseases. Curr. Opin. Immunol. 2010, 22:609-615.
124. Steinman L., Shoenfeld Y. From defining antigens to new therapies in multiple sclerosis: honoring the contributions of Ruth Arnon and Michael Sela. J. Autoimmun. 2014, 54:1-7.
125. Gershwin M.E., Shoenfeld Y. Abul Abbas: ane pitope of scholarship. J. Autoimmun. 2013, 45:1-6.